Covalys Biosciences AG
Executive Summary
Swiss start-up Covalys Biosciences AG believes it has developed a protein tag technology that will improve the way researchers label, immobilize and purify proteins. It's proprietary SNAP-tag, says the company, is more stale and versatile than existing protein tag technologies and can be employed anywhere proteins are studied.
You may also be interested in...
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.
Inside Bayer Oncology: An Interview With Robert LaCaze
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.